Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?

CONCLUSIONS: The power gain from the genotyping methods depends on the context. Because input parameters for early phase power calculations are often uncertain, these estimators are not recommended as primary endpoints for small trials unless supported by targeted data analysis.TRIAL REGISTRATIONS: NCT00866619, NCT02663700, NCT02143934.PMID:38115002 | DOI:10.1186/s12936-023-04802-0

Source: Cancer Control - December 20, 2023 Category: Cancer & Oncology Authors: Gail E Potter Viviane Callier Biraj Shrestha Sudhaunshu Joshi Ankit Dwivedi Joana C Silva Matthew B Laurens Dean A Follmann Gregory A Deye Source Type: research